Igmesine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Igmesine" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

7doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

doi.org

Roman FJ, Pascaud X, Martin B, Vauché D, Junien JL (June 1990). "JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites". The Journal of Pharmacy and Pharmacology. 42 (6): 439–40. doi:10.1111/j.2042-7158.1990.tb06588.x. PMID 1979628. S2CID 94116431.
Fishback JA, Robson MJ, Xu YT, Matsumoto RR (2010). "Sigma receptors: potential targets for a new class of antidepressant drug". Pharmacol. Ther. 127 (3): 271–82. doi:10.1016/j.pharmthera.2010.04.003. PMC 3993947. PMID 20438757.
O'Neill M, Caldwell M, Earley B, Canney M, O'Halloran A, Kelly J, Leonard BE, Junien JL (September 1995). "The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia". European Journal of Pharmacology. 283 (1–3): 217–25. doi:10.1016/0014-2999(95)00356-P. PMID 7498313.
Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA (July 2001). "Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant". Neuropharmacology. 41 (1): 138–49. doi:10.1016/S0028-3908(01)00049-1. PMID 11445194. S2CID 25003111.
Maurice T, Roman FJ, Su TP, Privat A (September 1996). "Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM)". Brain Research. 733 (2): 219–30. doi:10.1016/0006-8993(96)00565-3. PMID 8891305. S2CID 9306218.
Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011). "Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders". Expert Opin. Ther. Targets. 15 (5): 557–77. doi:10.1517/14728222.2011.560837. PMC 3076924. PMID 21375464.
Volz HP, Stoll KD (November 2004). "Clinical trials with sigma ligands". Pharmacopsychiatry. 37 Suppl 3: S214–20. doi:10.1055/s-2004-832680. PMID 15547788.

nih.gov

pubmed.ncbi.nlm.nih.gov

Roman FJ, Pascaud X, Martin B, Vauché D, Junien JL (June 1990). "JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites". The Journal of Pharmacy and Pharmacology. 42 (6): 439–40. doi:10.1111/j.2042-7158.1990.tb06588.x. PMID 1979628. S2CID 94116431.
Fishback JA, Robson MJ, Xu YT, Matsumoto RR (2010). "Sigma receptors: potential targets for a new class of antidepressant drug". Pharmacol. Ther. 127 (3): 271–82. doi:10.1016/j.pharmthera.2010.04.003. PMC 3993947. PMID 20438757.
O'Neill M, Caldwell M, Earley B, Canney M, O'Halloran A, Kelly J, Leonard BE, Junien JL (September 1995). "The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia". European Journal of Pharmacology. 283 (1–3): 217–25. doi:10.1016/0014-2999(95)00356-P. PMID 7498313.
Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA (July 2001). "Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant". Neuropharmacology. 41 (1): 138–49. doi:10.1016/S0028-3908(01)00049-1. PMID 11445194. S2CID 25003111.
Maurice T, Roman FJ, Su TP, Privat A (September 1996). "Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM)". Brain Research. 733 (2): 219–30. doi:10.1016/0006-8993(96)00565-3. PMID 8891305. S2CID 9306218.
Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011). "Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders". Expert Opin. Ther. Targets. 15 (5): 557–77. doi:10.1517/14728222.2011.560837. PMC 3076924. PMID 21375464.
Volz HP, Stoll KD (November 2004). "Clinical trials with sigma ligands". Pharmacopsychiatry. 37 Suppl 3: S214–20. doi:10.1055/s-2004-832680. PMID 15547788.

ncbi.nlm.nih.gov

Fishback JA, Robson MJ, Xu YT, Matsumoto RR (2010). "Sigma receptors: potential targets for a new class of antidepressant drug". Pharmacol. Ther. 127 (3): 271–82. doi:10.1016/j.pharmthera.2010.04.003. PMC 3993947. PMID 20438757.
Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011). "Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders". Expert Opin. Ther. Targets. 15 (5): 557–77. doi:10.1517/14728222.2011.560837. PMC 3076924. PMID 21375464.

semanticscholar.org

api.semanticscholar.org

Roman FJ, Pascaud X, Martin B, Vauché D, Junien JL (June 1990). "JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites". The Journal of Pharmacy and Pharmacology. 42 (6): 439–40. doi:10.1111/j.2042-7158.1990.tb06588.x. PMID 1979628. S2CID 94116431.
Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA (July 2001). "Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant". Neuropharmacology. 41 (1): 138–49. doi:10.1016/S0028-3908(01)00049-1. PMID 11445194. S2CID 25003111.
Maurice T, Roman FJ, Su TP, Privat A (September 1996). "Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM)". Brain Research. 733 (2): 219–30. doi:10.1016/0006-8993(96)00565-3. PMID 8891305. S2CID 9306218.